ARA-290
Symbol Ar · MW 1257 Da
EPO-derived peptide studied for nerve pain, inflammation and tissue protection.
- Discovered
- 2011
- Half-life
- 2 minutes
- Approval
- Investigational
Quick facts
- Category
- Recovery
- Route
- Injectable
- Molecular weight
- 1257 Da
- Half-life
- 2 minutes
- Discovered
- 2011
- Approval status
- Investigational
Reported effects
- Neuropathic pain relief
- Tissue protection
- Anti-inflammatory
Overview
ARA-290, also known as Cibinetide, is a tissue-protective peptide derived from erythropoietin-related research. It is studied for its potential role in reducing inflammation, supporting nerve health, and promoting cellular repair. Unlike erythropoietin, ARA-290 is designed to activate tissue-protective pathways without increasing red blood cell production. It is commonly associated with recovery, neuropathy research, inflammation control, and tissue repair support. As a recovery peptide, ARA-290 is most often discussed for its potential benefits in nerve-related discomfort, immune regulation, and protection against cellular stress.
Evidence context
ARA-290 evidence summary
Human clinical evidence
Human clinical evidence for ARA-290 may be limited, investigational, region-specific, or unavailable in the local source data. Peptidic avoids treating reported effects as proven clinical outcomes.
Animal, preclinical, or formulation evidence
ARA-290 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for ARA-290 as Investigational. The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- No established approved dosage; clinical research commonly uses 2–8 mg
- Typical Frequency
- Once daily or several times weekly depending on research protocol
There is no established FDA-approved dosage for this peptide. This information is for educational reference only and should not be treated as medical guidance.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on ARA-290.
Internal links
Related peptides
Frequently asked questions
What category is ARA-290 in?
ARA-290 is listed in the Recovery category on Peptidic.
What route is ARA-290 associated with?
ARA-290 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is ARA-290 approved?
Peptidic lists the approval status for ARA-290 as: Investigational. Approval details can vary by indication and jurisdiction.
Interested in ARA-290?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01